海南海药(000566) - 2015 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2015 was ¥811,866,612.33, representing an increase of 11.72% compared to ¥726,705,836.33 in the same period last year[21]. - The net profit attributable to shareholders was ¥114,098,500.31, up 19.84% from ¥95,207,255.26 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥95,297,355.88, reflecting a growth of 30.56% compared to ¥72,993,444.17 in the previous year[21]. - The basic earnings per share increased by 15.79% to ¥0.22 from ¥0.19 in the previous year[21]. - The company achieved operating revenue of 811,866,612.33 yuan, an increase of 11.72% compared to the same period last year, primarily due to the sales growth of gastrointestinal products and paclitaxel[33]. - Net profit attributable to shareholders reached 11,409.85 million yuan, reflecting a growth of 19.84% year-on-year[31]. - Operating profit rose to ¥133,799,115.54 compared to ¥99,755,248.01 in the previous period, marking a growth of about 34.1%[179]. - Net profit for the period reached ¥116,271,490.50, up from ¥99,153,260.10, reflecting an increase of approximately 17.4%[179]. - The company recorded a total comprehensive income of ¥116,354,699.14, up from ¥99,226,629.71, reflecting an increase of about 17.3%[181]. Assets and Liabilities - The company's total assets increased by 21.99% to ¥4,481,029,779.31 from ¥3,673,372,925.95 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 35.23% to ¥2,198,732,319.31 from ¥1,625,971,982.62 at the end of the previous year[21]. - The company's total liabilities increased to CNY 2,152,588,403.40 from CNY 1,944,883,639.74, representing a growth of approximately 10.7%[169]. - The company's equity increased to CNY 2,328,441,375.91 from CNY 1,728,489,286.21, reflecting a growth of around 34.6%[171]. - Current liabilities rose to CNY 1,388,175,964.21 from CNY 1,246,139,153.36, an increase of about 11.4%[169]. - Non-current assets totaled CNY 2,805,917,204.89, up from CNY 1,686,821,963.91, indicating a significant increase of approximately 66.5%[171]. Cash Flow - The company reported a significant improvement in net cash flow from operating activities, with a net outflow of only ¥4,736,231.02 compared to a net outflow of ¥41,908,850.07 in the same period last year, marking an 88.70% improvement[21]. - Operating cash inflow for the current period reached CNY 2,542,207,151.69, compared to CNY 1,373,785,839.77 in the previous period, indicating a significant increase of approximately 85.1%[192]. - Net cash flow from operating activities was CNY 624,950,644.09, a turnaround from a negative cash flow of CNY -94,303,218.75 in the previous period[192]. - Cash inflow from financing activities totaled CNY 1,527,501,325.48, compared to CNY 977,000,000.00 in the previous period, marking an increase of approximately 56.4%[189]. - The ending balance of cash and cash equivalents was CNY 350,104,189.89, compared to CNY 178,754,224.27 at the end of the previous period[189]. Investments and Acquisitions - The company completed the non-public issuance of 50,150,484 shares, raising a total of 500 million yuan to support future development[31]. - The company invested in Hunan Lianqiao Pharmaceutical Co., Ltd. to develop a traditional Chinese medicine platform and modern logistics[31]. - The company invested a total of ¥467,550,000 in external equity during the reporting period, a significant increase of 1,348.42% compared to ¥32,280,000 in the same period last year[45]. - The company has completed the acquisition of 75% of the shares of Kaiyuan Pharmaceutical, which has an annual production capacity of 80 tons of 7-ANCA[66]. - The company established a joint venture, Hunan Lianqiao Yaodu Pharmaceutical Co., Ltd., with an investment of 51 million yuan, holding a 51% stake[98]. Research and Development - Research and development expenses decreased by 61.97% to 10,567,787.13 yuan, indicating a reduction in investment compared to the previous year[35]. - The company has completed the construction and equipment procurement for the Hainan Haiyao Technology Center and product R&D project, with ongoing new drug development funded by its own resources[61]. Dividends and Shareholder Information - The company will not distribute cash dividends or issue bonus shares for this period[6]. - The company plans to distribute a cash dividend of CNY 0.30 per share, totaling CNY 16,360,212.96, based on a total share capital of 545,340,432 shares[80]. - The number of ordinary shareholders at the end of the reporting period was 23,919[147]. - Shenzhen Southern Tongzheng Investment Co., Ltd. holds 29.61% of the shares, amounting to 161,462,238 shares[147]. Regulatory and Compliance - The company’s semi-annual report for 2015 was not audited[123]. - The company did not engage in any asset acquisition or sale related transactions during the reporting period[104]. - There were no violations of regulations regarding external guarantees during the reporting period[117]. - The company’s financial report for the half-year period was not audited[163].